NCT04353661View on ClinicalTrials.gov

A Study Of ¹²⁹XE MRI To Assess Disease Progression In Patients With COPD Treated With Or Without Azithromycin And Standard-of-Care Medications

PHASE2TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 16, 2021

Primary Completion Date

June 29, 2023

Study Completion Date

June 29, 2023

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Azithromycin

Azithromycin will be administered orally.

OTHER

HP xenon (¹²⁹XE)

HP xenon (¹²⁹XE) will be administered at specified timepoints and the total dose bag volume should target 20% of the patient's forced vital capacity followed by a breath hold of up to 15 seconds

Trial Locations (2)

22908

University of Virginia Health System, Charlottesville

27705-2671

Duke Asthma Allergy and Airway Center, Durham

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY